Horizon Pharma Investment Limited a company registered in Bermuda under registration number EC50064 and is a wholly-owned subsidiary of Horizon Pharma plc (“the Parent”).

The Issuer’s Parent, Horizon Pharma, is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. Horizon Pharma markets a portfolio of products in arthritis, inflammation and orphan diseases.

The proceeds of the 2.50% senior notes due 15 March 2022 are intended for general corporate purposes.